Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E2609 in Early Alzheimer's Disease
CTR20191845Phase 3Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of elenbecestat in Alzheimer's disease (AD), sponsored by Eisai Co., Ltd.. Started Sep 2019; status: terminated.
02
Drugs
elenbecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20191845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191845.